Discordance of intrinsic subtype between primary tumor and lymph node metastasis in breast cancer patients.

IF 2 4区 生物学 Q3 CELL BIOLOGY
Yoko Omi, Tomoko Yamamoto, Yoji Nagashima, Takako Kamio, Kiyomi Horiuchi, Takahiro Okamoto
{"title":"Discordance of intrinsic subtype between primary tumor and lymph node metastasis in breast cancer patients.","authors":"Yoko Omi, Tomoko Yamamoto, Yoji Nagashima, Takako Kamio, Kiyomi Horiuchi, Takahiro Okamoto","doi":"10.14670/HH-18-989","DOIUrl":null,"url":null,"abstract":"<p><p>The heterogeneity of cancer cells between primary breast tumors and lymph node (LN) metastases at the initial therapy remains unclear. This study aimed to determine whether intrinsic subtypes of LN metastasis differ from those of primary breast tumors and how much additional information is obtained. Ninety-three breast cancer cases with LN metastasis were enrolled in the study. Immunohistochemistry for ER, PgR, HER2, and Ki-67 was performed for primary breast tumors and the largest LN metastases. The intrinsic subtype was determined as luminal A (ER<sup>+</sup>, PgR<sup>+</sup>, HER2<sup>-</sup>, Ki-67 index &le;20%), luminal B (ER<sup>+</sup>, HER2<sup>-</sup>, PgR<sup>-</sup> or PgR<sup>+</sup>, and Ki-67 index >20%), luminal B HER2 rich (ER<sup>+</sup>, HER2<sup>+</sup>), HER2 (ER<sup>-</sup>, HER2<sup>+</sup>), and triple-negative (ER<sup>-</sup>, PgR<sup>-</sup>, HER2<sup>-</sup>). ). The discordance ratios for intrinsic subtypes between the primary tumor and LN metastasis were analyzed. The discordance ratios for ER, PgR, HER2, and Ki-67 were 0/93 (0%), 7/93 (7.5%), 2/93 (2.2%), and 10/93 (10.8%), respectively. The discordance ratio for the intrinsic subtype was 9/93 (9.7%). Considering the intrinsic subtype of LN metastasis, the effects of additional chemotherapy and anti-HER2 therapy could be expected in 4/93 (4.3%) and 1/93 (1.1%) patients, respectively. The discordance ratio for the intrinsic subtype between the primary breast tumor and LN metastasis was 9.7%. Considering the intrinsic subtype of LN metastasis, additional medical therapy could be expected to be effective in 5/93 (5.4%) breast cancer cases with LN metastasis. Immunohistochemistry of metastatic LNs may be useful for planning adjuvant therapy when the analysis of the primary site is inconclusive.</p>","PeriodicalId":13164,"journal":{"name":"Histology and histopathology","volume":" ","pages":"18989"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Histology and histopathology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.14670/HH-18-989","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The heterogeneity of cancer cells between primary breast tumors and lymph node (LN) metastases at the initial therapy remains unclear. This study aimed to determine whether intrinsic subtypes of LN metastasis differ from those of primary breast tumors and how much additional information is obtained. Ninety-three breast cancer cases with LN metastasis were enrolled in the study. Immunohistochemistry for ER, PgR, HER2, and Ki-67 was performed for primary breast tumors and the largest LN metastases. The intrinsic subtype was determined as luminal A (ER+, PgR+, HER2-, Ki-67 index ≤20%), luminal B (ER+, HER2-, PgR- or PgR+, and Ki-67 index >20%), luminal B HER2 rich (ER+, HER2+), HER2 (ER-, HER2+), and triple-negative (ER-, PgR-, HER2-). ). The discordance ratios for intrinsic subtypes between the primary tumor and LN metastasis were analyzed. The discordance ratios for ER, PgR, HER2, and Ki-67 were 0/93 (0%), 7/93 (7.5%), 2/93 (2.2%), and 10/93 (10.8%), respectively. The discordance ratio for the intrinsic subtype was 9/93 (9.7%). Considering the intrinsic subtype of LN metastasis, the effects of additional chemotherapy and anti-HER2 therapy could be expected in 4/93 (4.3%) and 1/93 (1.1%) patients, respectively. The discordance ratio for the intrinsic subtype between the primary breast tumor and LN metastasis was 9.7%. Considering the intrinsic subtype of LN metastasis, additional medical therapy could be expected to be effective in 5/93 (5.4%) breast cancer cases with LN metastasis. Immunohistochemistry of metastatic LNs may be useful for planning adjuvant therapy when the analysis of the primary site is inconclusive.

乳腺癌患者原发肿瘤与淋巴结转移的内在亚型不一致。
原发性乳腺肿瘤和淋巴结(LN)转移的癌细胞在初始治疗时的异质性尚不清楚。本研究旨在确定LN转移的内在亚型是否与原发性乳腺肿瘤不同,以及获得了多少额外的信息。93例伴有淋巴结转移的乳腺癌患者参与了这项研究。对原发性乳腺肿瘤和最大的淋巴结转移进行ER、PgR、HER2和Ki-67的免疫组化检测。内源性亚型确定为luminal A (ER+、PgR+、HER2-、Ki-67指数20%)、luminal B (ER+、HER2-、PgR-或PgR+、Ki-67指数20%)、luminal B HER2丰富(ER+、HER2+)、HER2 (ER-、HER2+)和三阴性(ER-、PgR-、HER2-)。. 分析原发肿瘤与淋巴结转移的内在亚型不一致率。ER、PgR、HER2和Ki-67的不一致率分别为0/93(0%)、7/93(7.5%)、2/93(2.2%)和10/93(10.8%)。内在亚型的不一致性比为9/93(9.7%)。考虑到LN转移的内在亚型,4/93(4.3%)和1/93(1.1%)患者分别可以预期额外化疗和抗her2治疗的效果。原发性乳腺肿瘤与淋巴结转移的内在亚型不一致率为9.7%。考虑到LN转移的固有亚型,额外的药物治疗有望在5/93(5.4%)的乳腺癌LN转移病例中有效。当原发部位的分析不确定时,转移性LNs的免疫组织化学可能对规划辅助治疗有用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Histology and histopathology
Histology and histopathology 生物-病理学
CiteScore
3.90
自引率
0.00%
发文量
232
审稿时长
2 months
期刊介绍: HISTOLOGY AND HISTOPATHOLOGY is a peer-reviewed international journal, the purpose of which is to publish original and review articles in all fields of the microscopical morphology, cell biology and tissue engineering; high quality is the overall consideration. Its format is the standard international size of 21 x 27.7 cm. One volume is published every year (more than 1,300 pages, approximately 90 original works and 40 reviews). Each volume consists of 12 numbers published monthly online. The printed version of the journal includes 4 books every year; each of them compiles 3 numbers previously published online.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信